Praxis Precision Medicines, Inc. (PRAX) stock
PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$310.27−17.86 (-5.44%)
Close on Nov 16, 2026Market cap $8.66BP/E –Yield –
Praxis Precision Medicines r&d expenses
Research and development expenses are spending on new products and technology.
Praxis Precision Medicines's R&D Expenses for the twelve months ending Jun 30, 2026 was $290.71M, up 31.0% year over year. For fiscal 2025 it was $267.12M, up 75.3% from the year before. The highest annual figure on record is $267.12M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $267.12M | +75.3% |
| FY2024 | Dec 31, 2024 | $152.41M | +75.7% |
| FY2023 | Dec 31, 2023 | $86.77M | -44.0% |
| FY2022 | Dec 31, 2022 | $155.04M | +28.9% |
| FY2021 | Dec 31, 2021 | $120.26M | +167.4% |
| FY2020 | Dec 31, 2020 | $44.98M | +52.2% |
| FY2019 | Dec 31, 2019 | $29.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $69.42M | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $77.99M | +28.3% |
| Q4 FY2025 | Dec 31, 2025 | $77.51M | +37.7% |
| Q3 FY2025 | Sep 30, 2025 | $65.80M | +57.1% |
| Q2 FY2025 | Jun 30, 2025 | $63.01M | +131.1% |
| Q1 FY2025 | Mar 31, 2025 | $60.81M | +125.3% |
| Q4 FY2024 | Dec 31, 2024 | $56.29M | +206.1% |
| Q3 FY2024 | Sep 30, 2024 | $41.88M | +142.6% |
| Q2 FY2024 | Jun 30, 2024 | $27.26M | +6.4% |
| Q1 FY2024 | Mar 31, 2024 | $26.98M | +5.8% |
| Q4 FY2023 | Dec 31, 2023 | $18.39M | -35.1% |
| Q3 FY2023 | Sep 30, 2023 | $17.26M | -43.3% |
| Q2 FY2023 | Jun 30, 2023 | $25.61M | -41.3% |
| Q1 FY2023 | Mar 31, 2023 | $25.50M | -51.6% |
| Q4 FY2022 | Dec 31, 2022 | $28.33M | -34.9% |
| Q3 FY2022 | Sep 30, 2022 | $30.44M | -8.1% |
| Q2 FY2022 | Jun 30, 2022 | $43.62M | +69.9% |
| Q1 FY2022 | Mar 31, 2022 | $52.65M | +193.7% |
| Q4 FY2021 | Dec 31, 2021 | $43.51M | +167.4% |
| Q3 FY2021 | Sep 30, 2021 | $33.14M | +159.2% |
| Q2 FY2021 | Jun 30, 2021 | $25.68M | +183.7% |
| Q1 FY2021 | Mar 31, 2021 | $17.93M | +161.1% |
| Q4 FY2020 | Dec 31, 2020 | $16.27M | +185.5% |
| Q3 FY2020 | Sep 30, 2020 | $12.79M | +36.8% |
| Q2 FY2020 | Jun 30, 2020 | $9.05M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.87M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.70M | – |
| Q3 FY2019 | Sep 30, 2019 | $9.35M | – |
See a number that looks wrong?